To evaluate the efficacy of a short course of a lipid formulation of amphotericin B (L-AmB) for the treatment of Mediterranean visceral leishmaniasis (VL), an open prospective study was conducted. Forty-one children with parasitologically confirmed leishmaniasis received L-AmB, 10 mg/kg daily for 2 days. The comparison groups were 30 children who, in a previous study, were treated with L-AmB, 4...

OBJECTIVES To evaluate in vitro interactions between paromomycin sulphate and the antileishmanial drugs meglumine antimoniate, amphotericin B, miltefosine and azithromycin against intracellular Leishmania (Leishmania) infantum chagasi, Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis amastigotes in peritoneal mouse macrophages. METHODS First, drug susceptibility was a...

OBJECTIVE To explore the knowledge, beliefs, and practices (KBPs) regarding cutaneous leishmaniasis (CL) treatment held by an endemic population in Ecuador. METHODS A follow-up to research done several years before, this study used random cluster sampling to select 529 adults who lived in rural northwestern Ecuador. Data were collected over a 24-month period using in-depth interviews suppleme...

Sir, Follicular mucinosis (FM) is a non-speci¢c histological reaction pattern characterized by mucinous degeneration of the outer sheath of follicles and sebaceous glands, accompanied by a variable in£ammatory cell in¢ltrate (1). The clinical expression is extremely variable. It may occur as a primary disorder or associated with benign or malignant diseases (2 ^ 4). We describe a patient who de...

A case is reported of a 19-year-old woman, at week 24 of gestation, with visceral leishmaniosis. She was treated with meglumine antimoniate at a dose of 850 mg/day for 20 days. There occurred premature birth on day five of treatment and the neonate died one day after birth. Considering the importance of protozoiasis in our population and the rarity of the association with pregnancy, we resolved...

The authors report a case of disseminated cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis, in a 55 years old patient with 1,119 lesions distributed throughout the body. The patient resides in Sabáudia municipality, North of Paraná State, Southern Brazil, where there was no previous report of this form of leishmaniasis. Treatment with meglumine antimoniate was successful, alt...

This case report states a 25-year-old woman, residing in the city of Dezfool, Khuzestan Province, south of Iran with the diagnosis of cutaneous leishmaniasis in June 2008. Her skin lesion had developed from 8 months earlier as a nodule on her left arm, 1×3 cm in diameter. Because of severity of the lesion, we prescribed meglumine antimoniate intralesionally with giving up her breast feeding. Af...

We report a case of a 42 year-old female, who came to a leishmaniasis reference center in Rio de Janeiro, Brazil, presenting a cutaneous leishmaniasis lesion in the right forearm. Treatment with low-dose intramuscular meglumine antimoniate (MA) (5 mg Sb5+/kg/day) was initiated, with improvement after 28 days, although with the development of generalized eczema. After 87 days, the lesion worsene...